Endocrine Actions of Myostatin: Systemic Regulation of the IGF and IGF Binding Protein Axis
- 1 January 2011
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 152 (1), 172-180
- https://doi.org/10.1210/en.2010-0488
Abstract
Myostatin’s inhibitory actions on striated muscle growth are believed to be directly mediated by locally produced myostatin and possibly by IGF binding proteins (IGFBPs). We therefore measured skeletal muscle, heart, and liver expression, in neonates and adults, and circulating levels of various IGF axis components (IGF-I, IGFBP-1 to IGFBP-3, and acid labile subunit) in wild-type and mstn−/− mice. Compared with wild type, differences in muscle expression were tissue specific, although IGF-I receptor expression was higher in all mstn−/− neonatal tissues and in adult gastrocnemius. Liver expression of several components also differed between genotype as IGF-I receptor, IGFBP-3 and IGFBP-5 expression was higher in mstn−/− neonates and IGF-I and IGFBP-3 in adults. Circulating IGF-I levels were also higher in mstn−/− adults, whereas IGFBP-1 and IGFBP-2 levels were lower. Comparing IGF-I:IGFBP molar ratios suggested that the relative IGF-binding capacity was potentially lower in mstn−/− mice, and thus, total and “free” IGF-I levels may be elevated. This in turn may increase negative feedback control on GH, because mstn−/− liver weights were lower. Bone growth was similar in both genotypes, suggesting that changes in circulating IGF-I may be more important to muscle, whose mass is enhanced in mstn−/− mice, than to bone. Myostatin receptors, but not myostatin itself, are expressed in the liver. Changes in hepatic production of circulating IGF axis components could therefore result from the loss of endocrine myostatin. Thus, myostatin may inhibit striated muscle growth directly at the cellular level and indirectly through systemic effects on the IGF axis.Keywords
This publication has 57 references indexed in Scilit:
- A rapid, valid and inexpensive assay for measuring epiphyseal plates in mouse tibiaGrowth Hormone & IGF Research, 2010
- Myostatin represses physiological hypertrophy of the heart and excitation–contraction couplingJournal Of Physiology-London, 2009
- Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube sizeAmerican Journal of Physiology-Cell Physiology, 2009
- Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activityProceedings of the National Academy of Sciences of the United States of America, 2009
- The decrease in mature myostatin protein in male skeletal muscle is developmentally regulated by growth hormoneJournal Of Physiology-London, 2009
- Serum complexes of insulin‐like growth factor‐1 modulate skeletal integrity and carbohydrate metabolismThe FASEB Journal, 2008
- Clinical, Agricultural, and Evolutionary Biology of Myostatin: A Comparative ReviewEndocrine Reviews, 2008
- Regulation of muscle mass by growth hormone and IGF‐IBritish Journal of Pharmacology, 2008
- Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunitGrowth Hormone & IGF Research, 2008
- Myostatin Regulates Cardiomyocyte Growth Through Modulation of Akt SignalingCirculation Research, 2006